Key Insights

Highlights

Success Rate

89% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

5.0%

1 terminated out of 20 trials

Success Rate

88.9%

+2.4% vs benchmark

Late-Stage Pipeline

30%

6 trials in Phase 3/4

Results Transparency

0%

0 of 8 completed with results

Key Signals

89% success

Data Visualizations

Phase Distribution

15Total
Not Applicable (5)
P 1 (2)
P 2 (2)
P 3 (4)
P 4 (2)

Trial Status

Completed8
Recruiting5
Unknown2
Terminated1
Not Yet Recruiting1
Suspended1

Trial Success Rate

88.9%

Benchmark: 86.5%

Based on 8 completed trials

Clinical Trials (20)

Showing 20 of 20 trials
NCT03455959Not ApplicableActive Not RecruitingPrimary

Lung-Resident Memory Th2 Cells in Asthma

NCT05720325Phase 2RecruitingPrimary

Dupilumab Effects Against Aeroallergen Challenge

NCT05478824CompletedPrimary

IL13 Signaling in Allergic Asthma

NCT04109807Not ApplicableSuspendedPrimary

Effects of Low Dose Ozone on Airway Inflammatory Responses in Adults With Asthma - Sedentary Nasal Ozone (Asthma SNOZ)

NCT04898283Phase 3Recruiting

Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses.

NCT04435990Phase 3Recruiting

Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites

NCT04891237Phase 3Recruiting

Efficacy and Safety Evaluation for the Treatment of Allergy Against Grass and Olive Pollen

NCT03983603Not ApplicableRecruitingPrimary

Plant Stanol Esters and Preventing Asthma Symptoms

NCT06063044Completed

Food-specific IgG4-guided Elimination Diets Improve Allergy Symptoms in Children

NCT06027073Phase 4Not Yet RecruitingPrimary

Biologics and Sublingual Immunotherapy

NCT05740748Phase 2UnknownPrimary

Tezepelumab and Methacholine Airway Hyperresponsiveness in Participants With Mild Allergic Asthma

NCT04035109Phase 1WithdrawnPrimary

Anakinra as a Rescue Treatment for Allergic Inflammation

NCT05352126Not ApplicableUnknownPrimary

Effects of Puressentiel Purifying Spray on Asthma Control in Patients With Mild to Moderate Allergy-induced Asthma.

NCT03468790Phase 3CompletedPrimary

Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma.

NCT03705325Not ApplicableCompleted

Evaluating Asthma Exacerbation-induced Changes in Lung Function With a Home-based Spirometer

NCT03112577Phase 1CompletedPrimary

Study of REGN3500 and Dupilumab in Patients With Asthma

NCT02990117CompletedPrimary

ICS Treatment Compliance of Asthma Patients

NCT03563521Completed

Identifying Serum Cytokine Profiles of Distinct Inflammatory Phenotypes in Severe Asthma

NCT02953106Phase 4TerminatedPrimary

Effects of Intranasal Fluticasone Plus Azelastine on Airway Inflammation in Patients With Asthma & Allergic Rhinitis

NCT01104012Completed

Validation of Proteomic Analyses for Allergic Asthma and Rhinitis

Showing all 20 trials

Research Network

Activity Timeline